In the treatment of patients with community-acquired bacterial pneumonia (CABP), omadacycline is as effective as moxifloxacin at inducing response in patients with Pneumonia Patient Outcomes Research Team (PORT) risk class III and IV, according to data from the phase III OPTIC* trial.
Mild cases are estimated to comprise over half of the overall asthma population. Unlike in most other chronic conditions, patients with mild asthma are still at risk of serious outcomes, including death, according to Professor Helen Reddel of the Woolcock Institute of Medical Research, University of Sydney, who spoke at the Advances in Medicine 2020 virtual conference. [Eur Respir J 2007;30:403-406; Can Respir J 2010;17:74-80; Royal College of Physicians. Why asthma still kills: National Review of Asthma Deaths Confidential Enquiry Report. London, 2014]
Anxiety and depression due to COVID-19 affected one in three adults in the general population, with women, younger adults, and those of lower socioeconomic status being particularly at risk, a study finds — thus highlighting the need for mental health interventions in high-risk groups.
SARS-CoV-2 transmission from asymptomatic individuals could account for more than half of all transmissions, according to estimates from a modelling study and data from a real-world study —suggesting that isolation of symptomatic cases alone is insufficient for controlling the ongoing spread of SARS-CoV-2.
Pre-existing hepatitis B virus (HBV) infection does not appear to worsen COVID-19 outcomes, a study from China showed. However, significant differences in blood counts and biochemistry were observed in patients with both conditions compared with those with COVID-19 mono-infection.
The interleukin (IL)-1β antibody canakinumab has demonstrated a promising efficacy signal in patients with COVID-19-related pneumonia, reducing the need for invasive mechanical ventilation and improving clinical status, according to a study.
A study from England suggests that cancer survivors, particularly haematological cancer survivors, may have a long-term risk of hospitalization or death from influenza compared with individuals with no history of cancer. The study authors believe these findings may help identify cancer survivors at risk for severe COVID-19 outcomes.